Wyeth two-rod levonorgestrel contraceptive implant launch awaits approval of new insertion trocar.
WYETH-AYERST TWO-ROD LEVONORGESTREL IMPLANT LAUNCH AWAITS completion of research to support a 510(k) application for a new trocar, the company indicated. FDA approved Wyeth-Ayerst's NDA (20-627) for the contraceptive Aug. 15. The two-rod, 150 mg implant would provide three years of contraception; Wyeth's six-rod Norplant levonorgestrel implant provides five years of contraception.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth